Press Releases Pharnext SCA

Equities

ALPHA

FR001400N1P4

Market Closed - Euronext Paris Other stock markets 11:35:00 2024-04-26 am EDT			5-day change	1st Jan Change
0.1499 ^EUR	-8.88%		-12.75%	-92.50%

Apr. 25	Pharnext: share price rises on encouraging comments	CF
Mar. 06	Pharnext: listing suspended pending further update	CF

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pharnext Sca : Pharnext takes full stock of its operating, strategic and financial situation	Mar. 11	AT
Pharnext : Présentation corporate de Pharnext	Mar. 05	PU
Pharnext Sca : Pharnext progresses in analyzing data from pivotal Phase III study of PXT3003 in Charcot-Marie-Tooth disease type 1A	Feb. 28	AT
Pharnext Sca : Pharnext commits to a drastic cost-cutting plan and receives support from its financial partners to further enhance the value of its drug candidate for Charcot-Marie-Tooth disease type 1A	Jan. 17	AT
Pharnext Sca : Pharnext commits to a drastic cost-cutting plan to further enhance the value of its drug candidate for Charcot-Marie-Tooth disease type 1A	Jan. 17	AT
Pharnext Sca : Pharnext intends to prepare registration and marketing authorization dossiers for PXT3003, its drug candidate in Charcot-Marie-Tooth disease type 1A	Dec. 19	AT
Pharnext Sa : Pharnext reports topline results from the pivotal Phase III clinical trial (PREMIER trial) of PXT3003 in Charcot-Marie-Tooth disease type 1A	Dec. 11	AT
Pharnext : Document AMF CP. 2023E941731	Dec. 08	PU
Pharnext : Document AMF CP. 2023E941502	Dec. 07	PU
Pharnext Sa : Pharnext announces database lock for PXT3003 pivotal Phase III clinical study (PREMIER trial) in Charcot-Marie-Tooth disease type 1A, last step before topline results publication	Dec. 04	AT
Pharnext : Document AMF CP. 2023E940554	Dec. 01	PU
Pharnext Sa : Pharnext unveils new calendar for negotiations valuing its drug candidate in Charcot-Marie-Tooth disease type 1A	Nov. 27	AT
Pharnext Sa : Pharnext announces being at D-18 before publication of topline results from pivotal Phase III clinical trial (PREMIER trial) in Charcot-Marie-Tooth disease type 1A	Nov. 23	AT
Pharnext Sa : Pharnext announces successful manufacturing of registration batches of PXT3003 in the United States	Nov. 20	AT
Pharnext : Document AMF CP. 2023E938112	Nov. 14	PU
Pharnext : Document AMF CP. 2023E937889	Nov. 13	PU
Pharnext : Document AMF CP. 2023E937247	Nov. 08	PU
Pharnext : receives a new offer valuing its drug candidate for Charcot-Marie-Tooth disease type 1A at more than €500m and the support of its financial partners	23-10-30	PU
Pharnext Sa : Pharnext receives a new offer valuing its drug candidate for Charcot-Marie-Tooth disease type 1A at more than EUR500m and the support of its financial partners	23-10-30	AT
Pharnext : Document AMF CP. 2023E933547	23-10-18	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Pharnext SCA

Equities

ALPHA

FR001400N1P4

Press Releases

Filters